vs
Coeptis Therapeutics Holdings, Inc.（COEP）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Arcadia Biosciences, Inc.的季度营收约是Coeptis Therapeutics Holdings, Inc.的1.0倍（$901.0K vs $862.0K），Coeptis Therapeutics Holdings, Inc.净利率更高（-146.5% vs -148.3%，领先1.8%）
Coeptis Therapeutics Holdings, Inc.是一家临床阶段生物制药企业，专注于开发创新癌症免疫疗法，包括细胞疗法、抗体类治疗候选药物，以满足难治性恶性肿瘤患者未被覆盖的医疗需求，主要在美国运营，推进旗下多个肿瘤领域管线的研发工作。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
COEP vs RKDA — 直观对比
营收规模更大
RKDA
是对方的1.0倍
$862.0K
净利率更高
COEP
高出1.8%
-148.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $862.0K | $901.0K |
| 净利润 | $-1.3M | $-1.3M |
| 毛利率 | 94.8% | 21.4% |
| 营业利润率 | -230.6% | -152.8% |
| 净利率 | -146.5% | -148.3% |
| 营收同比 | — | -25.8% |
| 净利润同比 | 55.1% | 67.1% |
| 每股收益（稀释后） | $0.05 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COEPRKDA
| Q4 25 | $862.0K | $901.0K | ||
| Q3 25 | $237.4K | $1.3M | ||
| Q2 25 | $200.7K | $1.5M | ||
| Q1 25 | $62.9K | $1.2M | ||
| Q4 24 | $0 | $1.2M | ||
| Q3 24 | $0 | $1.5M | ||
| Q2 24 | $0 | $1.3M | ||
| Q1 24 | $0 | $987.0K |
净利润COEPRKDA
| Q4 25 | $-1.3M | $-1.3M | ||
| Q3 25 | $-2.9M | $856.0K | ||
| Q2 25 | $-4.3M | $-4.5M | ||
| Q1 25 | $-3.4M | $2.6M | ||
| Q4 24 | $-2.8M | $-4.1M | ||
| Q3 24 | $-1.8M | $-1.6M | ||
| Q2 24 | $-3.0M | $1.1M | ||
| Q1 24 | $-3.0M | $-2.4M |
毛利率COEPRKDA
| Q4 25 | 94.8% | 21.4% | ||
| Q3 25 | 81.0% | 32.1% | ||
| Q2 25 | 77.5% | 43.4% | ||
| Q1 25 | 28.2% | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率COEPRKDA
| Q4 25 | -230.6% | -152.8% | ||
| Q3 25 | -1043.2% | -88.5% | ||
| Q2 25 | -2252.9% | -34.4% | ||
| Q1 25 | -6452.6% | 44.2% | ||
| Q4 24 | — | -187.7% | ||
| Q3 24 | — | -114.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -160.9% |
净利率COEPRKDA
| Q4 25 | -146.5% | -148.3% | ||
| Q3 25 | -1220.8% | 65.7% | ||
| Q2 25 | -2159.9% | -306.4% | ||
| Q1 25 | -5440.9% | 216.6% | ||
| Q4 24 | — | -334.5% | ||
| Q3 24 | — | -104.9% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | -245.5% |
每股收益（稀释后）COEPRKDA
| Q4 25 | $0.05 | $-0.97 | ||
| Q3 25 | $-0.58 | $0.62 | ||
| Q2 25 | $-1.17 | $-3.26 | ||
| Q1 25 | $-1.11 | $1.90 | ||
| Q4 24 | $-5.35 | $-2.99 | ||
| Q3 24 | $-0.05 | $-1.18 | ||
| Q2 24 | $-0.08 | $0.78 | ||
| Q1 24 | $-0.08 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $676.6K | $4.6M |
| 总债务越低越好 | $150.0K | — |
| 股东权益账面价值 | $13.6M | $4.1M |
| 总资产 | $16.2M | $6.5M |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资COEPRKDA
| Q4 25 | $676.6K | $4.6M | ||
| Q3 25 | $421.7K | $5.9M | ||
| Q2 25 | $990.6K | $4.4M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $4.2M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | — | $8.1M | ||
| Q1 24 | — | $8.5M |
总债务COEPRKDA
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $2.3M | — |
股东权益COEPRKDA
| Q4 25 | $13.6M | $4.1M | ||
| Q3 25 | $10.4M | $5.4M | ||
| Q2 25 | $6.1M | $4.5M | ||
| Q1 25 | $6.5M | $8.9M | ||
| Q4 24 | $3.4M | $6.2M | ||
| Q3 24 | $4.8M | $10.3M | ||
| Q2 24 | $-442.6K | $11.7M | ||
| Q1 24 | $-1.1M | $10.6M |
总资产COEPRKDA
| Q4 25 | $16.2M | $6.5M | ||
| Q3 25 | $14.2M | $8.6M | ||
| Q2 25 | $12.2M | $7.8M | ||
| Q1 25 | $13.5M | $13.0M | ||
| Q4 24 | $8.9M | $13.5M | ||
| Q3 24 | $9.0M | $15.2M | ||
| Q2 24 | $4.2M | $17.4M | ||
| Q1 24 | $3.9M | $16.0M |
负债/权益比COEPRKDA
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.6M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流COEPRKDA
| Q4 25 | $-8.6M | $-861.0K | ||
| Q3 25 | $-2.2M | $-257.0K | ||
| Q2 25 | $-2.4M | $-2.0M | ||
| Q1 25 | $-2.4M | $-1.6M | ||
| Q4 24 | $-6.6M | $-2.2M | ||
| Q3 24 | $-1.9M | $-1.8M | ||
| Q2 24 | $-1.4M | $-2.5M | ||
| Q1 24 | $-1.9M | $-3.2M |
自由现金流COEPRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率COEPRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度COEPRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率COEPRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
